Business UpdateJul 31, 2026, 08:22 AM
SciSparc Subsidiary NeuroThera Achieves Quantum Platform Milestone
AI Summary
SciSparc Ltd. announced that its majority-owned subsidiary, NeuroThera Labs Inc., achieved a significant technological milestone. NeuroThera's quantum sampling workflow platform for clinical trials data analytics successfully demonstrated a complete end-to-end hybrid quantum-classical workflow. This platform can process real-world clinical data through quantum-enabled analytical processing to generate clinically interpretable insights, executed within a quantum simulation environment. The development, advanced through CliniQuantum Ltd. (54.01% owned by NeuroThera), aims to expand supported datasets and optimize quantum algorithms for clinical research and precision medicine.
Key Highlights
- SciSparc's subsidiary, NeuroThera, achieved a milestone for its quantum sampling platform.
- The platform demonstrated a complete hybrid quantum-classical workflow for clinical data analytics.
- It processes real-world clinical data through quantum-enabled analytical processing.
- The workflow was executed within a quantum simulation environment.
- NeuroThera holds 54.01% in CliniQuantum Ltd., which advances the platform.
- The platform aims to uncover non-obvious patterns in complex biomedical datasets.
- Future plans include expanding dataset scale and optimizing quantum algorithms.
Price Impact
More from SPRC